Plasma Pro-Enkephalin A and Incident Cognitive Impairment: The Reasons for Geographic and Racial Differences in Stroke Cohort
- PMID: 37260023
- PMCID: PMC10381999
- DOI: 10.1161/JAHA.122.029081
Plasma Pro-Enkephalin A and Incident Cognitive Impairment: The Reasons for Geographic and Racial Differences in Stroke Cohort
Abstract
Background Cardiovascular disease is a risk factor for cognitive impairment. Evidence links both lower and higher concentration of the circulating opioid pro-enkephalin A (PENK-A) with stroke risk. We studied the association of plasma PENK-A with incident cognitive impairment. Methods and Results REGARDS (Reasons for Geographic and Racial Differences in Stroke) is a prospective cohort study of 30 239 adults enrolled from 2003 to 2007. Baseline PENK-A was measured in a nested case-control study of 462 participants who developed cognitive impairment over 4.7 years, and 556 controls. Logistic regression and spline plots adjusted for confounders estimated odds ratios (ORs) of cognitive impairment by baseline PENK-A. Interaction terms tested for differences in associations by age, sex, and race. Baseline PENK-A was comparable between cases and controls. There were significant differences in the association of PENK-A with cognitive impairment by sex and age (adjusted P=0.003 and 0.06, respectively). In women but not men, spline plots showed that higher and lower PENK-A were associated with decreased odds of cognitive impairment (ORs for 10th and 90th percentiles versus median, 0.65 [95% CI, 0.43-0.96] and 0.64 [95% CI, 0.41-0.99]), with no difference by age. In men ≥65 years of age but not younger men, higher PENK-A was associated with decreased odds for cognitive impairment (OR for fourth versus first quartile 0.47 [95% CI, 0.22-0.99]); this pattern was not confirmed with spline plotting. Conclusions High and low levels of circulating opioid PENK-A were associated with decreased odds of future cognitive impairment in specific subgroups. Additional research is warranted to understand the biology underlying this association and the observed differences by sex.
Keywords: cognitive impairment; cohort study; opioid; pro‐enkephalin; risk factor.
Figures


Similar articles
-
Plasma Pro-Enkephalin A and Ischemic Stroke Risk: The Reasons for Geographic and Racial Differences in Stroke Cohort.J Stroke Cerebrovasc Dis. 2022 Feb;31(2):106237. doi: 10.1016/j.jstrokecerebrovasdis.2021.106237. Epub 2021 Dec 9. J Stroke Cerebrovasc Dis. 2022. PMID: 34896817 Free PMC article.
-
Pro-Neurotensin/Neuromedin N and Risk of Cognitive Impairment in a Prospective Study.J Alzheimers Dis. 2020;76(4):1403-1412. doi: 10.3233/JAD-200456. J Alzheimers Dis. 2020. PMID: 32623400
-
Serum magnesium concentration and incident cognitive impairment: the reasons for geographic and racial differences in stroke study.Eur J Nutr. 2021 Apr;60(3):1511-1520. doi: 10.1007/s00394-020-02353-7. Epub 2020 Jul 31. Eur J Nutr. 2021. PMID: 32737612 Free PMC article.
-
N-Terminal Pro-B-Type Natriuretic Peptide and Risk of Future Cognitive Impairment in the REGARDS Cohort.J Alzheimers Dis. 2016 Sep 6;54(2):497-503. doi: 10.3233/JAD-160328. J Alzheimers Dis. 2016. PMID: 27567834
-
Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke: A systematic review and meta-analysis.Ageing Res Rev. 2020 Jan;57:100962. doi: 10.1016/j.arr.2019.100962. Epub 2019 Sep 7. Ageing Res Rev. 2020. PMID: 31505259
Cited by
-
Proenkephalin Levels and Its Determinants in Patients with End-Stage Kidney Disease Treated with Hemodialysis and Peritoneal Dialysis.Int J Mol Sci. 2023 Oct 9;24(19):15015. doi: 10.3390/ijms241915015. Int J Mol Sci. 2023. PMID: 37834463 Free PMC article.
References
-
- Alzheimer’s Disease International . 2019. World Alzheimer Report 2019: Attitudes to dementia. London: Alzheimer’s Disease International.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous